The management of chronic kidney disease involves addressing both the underlying cause and the complications of the disease. Early intervention can slow the progression of CKD, prevent cardiovascular events, and improve patient outcomes. Key management strategies include:
Blood Pressure Control
Optimal blood pressure control is essential to slowing CKD progression. Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) are the first-line therapies for patients with CKD, particularly those with proteinuria, as they reduce intraglomerular pressure and proteinuria.
Glycemic Control
For diabetic patients, tight glycemic control (HbA1c <7%) is important to prevent the development and progression of diabetic nephropathy. Newer antidiabetic medications such as sodium-glucose cotransporter-2 (SGLT2) inhibitors and GLP-1 receptor agonists have been shown to provide renal protection.
Dietary Modification
Dietary interventions, such as reducing salt intake to less than 2g/day, managing protein intake, and avoiding high-potassium foods, can help mitigate its progression. In patients with hyperphosphatemia, phosphate binders may be necessary to control serum phosphorus levels.
Management of Anemia
Anemia of chronic kidney disease is managed with erythropoiesis-stimulating agents (ESAs) and iron supplementation to maintain hemoglobin levels between 10 and 11.5 g/dL. Monitoring and addressing iron deficiency is also crucial in managing anemia.
Bone Mineral Disease Management
Chronic kidney disease-Mineral Bone Disorder (CKD-MBD) is treated by controlling serum phosphate levels, using calcium-based or non-calcium-based phosphate binders, and supplementing active vitamin D to suppress secondary hyperparathyroidism.
Renal Replacement Therapy (RRT)
As CKD progresses to dnd-Stage renal disease (ESRD), patients may require renal replacement therapy, including hemodialysis, peritoneal dialysis, or kidney transplantation. Early referral to a nephrologist for RRT planning is essential for optimizing outcomes and avoiding emergency dialysis initiation.
| Domain | Approach and target |
|---|---|
| Blood pressure | ACE inhibitors or ARBs first-line, particularly with proteinuria, because they reduce intraglomerular pressure and proteinuria |
| Glycemic control | HbA1c below 7% in diabetes; SGLT2 inhibitors and GLP-1 receptor agonists add renal protection |
| Diet | Salt below 2 g/day, managed protein intake, avoidance of high-potassium foods; phosphate binders where hyperphosphatemia is present |
| Anemia | Erythropoiesis-stimulating agents with iron supplementation, maintaining hemoglobin between 10 and 11.5 g/dL |
| Bone mineral disorder | Control serum phosphate with calcium-based or non-calcium-based binders and supplement active vitamin D to suppress secondary hyperparathyroidism |
| Renal replacement therapy | Hemodialysis, peritoneal dialysis or transplantation as CKD reaches end-stage; early nephrology referral avoids emergency dialysis initiation |
